Cód QR

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Background: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. Methods: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 parti...

Cur síos iomlán

Sábháilte in:
Príomhchruthaitheoirí: Lihua Wu, Zhe Zhang, Hainv Gao, Yuhua Li, Lihua Hou, Hangping Yao, Shipo Wu, Jian Liu, Ling Wang, You Zhai, Huilin Ou, Meihua Lin, Xiaoxin Wu, Jingjing Liu, Guanjing Lang, Qian Xin, Guolan Wu, Li Luo, Pei Liu, Jianzhong Shentu, Nanping Wu, Jifang Sheng, Yunqing Qiu, Wei Chen, Lanjuan Li
Formáid: Artigo
Teanga:Inglês
Foilsithe / Cruthaithe: Taylor & Francis Group 2017-09-01
Sraith:Human Vaccines & Immunotherapeutics
Ábhair:
ad5-ebov
gp antibody
immunogenicity
safety
t-cell response
Rochtain ar líne:http://dx.doi.org/10.1080/21645515.2017.1342021
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla